| The following article features coverage from the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting. Click here to read more of Cancer Therapy Advisor‘s conference coverage. |
Compared with best supportive care, adjuvant atezolizumab improves disease-free survival (DFS) among patients with resected stage IB-IIIA non-small cell lung cancer (NSCLC), according to research being presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting.
In the phase 3 IMpower010 study (ClinicalTrials.gov Identifier: NCT02486718), researchers compared adjuvant atezolizumab to best supportive care in patients with stage IB-IIIA NSCLC who had undergone surgery and received adjuvant chemotherapy.
Of the 1280 patients who received a cisplatin-based chemotherapy regimen, 1005 patients were randomly assigned to receive either adjuvant atezolizumab (507 patients) or best supportive care (498 patients).
Continue Reading
The median follow-up time at data cutoff (January 2021) was 32.2 months in the intention-to-treat population. The median DFS was not reached in the atezolizumab group and was 37.2 months in the best supportive care group (hazard ratio, 0.81; P =.04).
In a subgroup of patients with stage II-IIIA disease, the median DFS was 42.3 months in the atezolizumab group (442 patients) and 35.3 months in the best supportive care group (440 patients; hazard ratio, 0.79; P =.02).
In a subgroup of patients with both stage II-IIIA disease and PD-L1 expression of at least 1%, the median DFS was not reached in the atezolizumab group (248 patients) and was 35.3 months in the best supportive care group (228 patients; hazard ratio, 0.66; P =.004).
Adverse events (AEs) of any grade occurred in 92.7% of patients in the atezolizumab group and 70.7% of patients in the best supportive care group. Grade 3-4 AEs occurred in 21.8% and 11.5% of patients, respectively.
AEs leading to treatment discontinuation occurred in 18.2% of patients in the atezolizumab group, and grade 5 treatment-related AEs occurred in 0.8% of patients in this group.
Future reports will provide overall survival data.
Disclosures: This research was supported by F. Hoffmann-La Roche. Some study authors declared affiliations with biotech, pharmaceutical, and/or device companies. Please see the original reference for a full list of authors’ disclosures.
Read more of Cancer Therapy Advisor’s coverage of the 2021 ASCO Annual Meeting by visiting the conference page.
Reference
Wakelee H, Altorki N, Zhou C, et al. IMpower010: Primary results of a phase III global study of atezolizumab versus best supportive care after adjuvant chemotherapy in resected stage IB-IIIA non-small cell lung cancer (NSCLC). J Clin Oncol. 2021;39:(suppl 15; abstr 8500). doi:10.1200/JCO.2021.39.15_suppl.8500
